About Dragonfly TherapeuticsDragonfly Therapeutics is a discovery-stage company developing drugs to stimulate immune responses against cancer. We are developing novel first-in-class therapeutics targeted at natural killer cells and other cells of the innate immune system. Our scientific founders are major figures in cancer biology and immunology and have launched Dragonfly to harness the power of the immune system to provide breakthrough cancer treatments for patients.
Co-Founder and CEO: William Haney
Co-Founder: Dr. Tyler Jacks
Co-Founder: Dr. David Raulet
22 articles with Dragonfly Therapeutics
Dragonfly to receive payment for the first Opt-In from AbbVie as part of a multi-target collaboration launched just over 1 year ago.
Dragonfly Therapeutics and Bristol Myers Squibb Announce Exclusive Global License for Dragonfly’s IL-12 Investigational Immunotherapy Program
Agreement Includes DF6002, With Potential to Advance Treatment of Solid Tumors and Hematology Indications
Dragonfly Therapeutics ("Dragonfly"), a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, and AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced a multi-target research collaboration designed to advance a number of Dragonfly's novel NK cell engager-based immunotherapies for autoimmune and oncology indications.
At the center of the agreement are Dragonfly’s novel NK cell engager-based immunotherapies.
Dragonfly Therapeutics Adds World-Leading Cancer Immunotherapy Pioneer to its Scientific Advisory Board
Dr. Alan Korman, renowned for his work leading to the development the first approved checkpoint inhibitor cancer therapies, joins Dragonfly's scientific team.
Both Nobel Prize Winner and World-Leading Clinician Join Dragonfly Therapeutics' Scientific Leadership Team
Dr. Allison joins Nobel Prize winner Harold Varmus, M.D., and an outstanding group of clinicians and scientists on Dragonfly's Scientific Advisory Board.
MD Anderson Cancer Center and Dragonfly Therapeutics announce strategic collaboration to take new immunotherapy candidates into clinical trials
The University of Texas MD Anderson Cancer Centerand Dragonfly Therapeutics, Inc., today announced a strategic collaboration to bring Dragonfly’s TriNKET™ (tri-specific natural killer cell engager therapy) immunotherapy drug candidates to patients in clinical trials beginning in 2019.
Dragonfly Therapeutics Announces Celgene In-license of First Two TriNKET™ Immunotherapy Drug Candidates
Celgene licenses two TriNKET™ immunotherapy drug candidates built by Dragonfly for $24m plus milestones and royalties
Dragonfly Therapeutics Announces Expansion of its Strategic Collaboration with Celgene, Doubling the Number of Programs and Including Targets for Solid Tumor Indications
Celgene receives options to double its access to Dragonfly candidate natural killer (NK) cell engager immunotherapies, expanding to a total of eight collaboration targets between the two companies, and broadening the collaboration to include solid tumor targets
Dragonfly Therapeutics Adds World-Leading Cancer Immunotherapy Experts to its Scientific Advisory Board
Dragonfly Therapeutics, Inc. ("Dragonfly"), today announced the addition of world-leading cancer immunotherapy experts Dr. Elizabeth M. Jaffee, Dr. Suzanne Topalian, and Dr. Lewis Lanier, to its Scientific Advisory Board.
Dragonfly Therapeutics struck a licensing agreement worth up to $695 million with Merck. Merck will license exclusive rights to Dragonfly’s TriNKET technology platform for a number of solid-tumor programs, the company announced today.
Dragonfly Therapeutics Announces New Multi-Target Collaboration with Merck to Use Dragonfly's Proprietary TriNKET™ Platform to Develop Novel Drug Candidates for Patients with Solid Tumors
Merck receives exclusive options to license a number of Dragonfly's candidate natural killer (NK) cell engager immunotherapies for solid tumor malignancies.
Dr. Cuillerot will head clinical development of Dragonfly's novel Natural Killer cell-based immunotherapies.
Dragonfly Adds Natural Killer Cell-Based Cancer Immunotherapy Expert To Its Scientific Advisory Board
Dragonfly Release: Company Adds Technology Investor And Leading Advertising Company CEO To Its Board Of Directors